LFVNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Lifevantage Corp
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Aug 27, 2026
$5.98−0.02 (-0.33%)
Close on Oct 19, 2026
- Market cap
- $74.97M
- P/E (TTM)
- 15.0
- Dividend yield
- 3.09%
Margins
Share of revenue, fiscal years 2012 to 2026
Gross margin
77.6%−5.1 pts over 5 years
Operating margin
3.3%−4.7 pts over 5 years
Net margin
2.8%−3.1 pts over 5 years
Growth rates
Compound annual growth to fiscal 2026
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -20.1% | -5.1% | -3.7% | -1.2% | |
| Gross profit | -22.9% | -5.9% | -4.9% | -2.0% | |
| Operating income | -50.0% | +12.7% | -19.1% | -7.6% | |
| Net income | -48.3% | +25.9% | -17.0% | -1.8% | |
| EPS, diluted | -46.7% | +26.0% | -15.0% | -0.5% | |
| Free cash flow | -36.5% | +21.0% | -11.9% | +2.0% | |
| Dividend per share | +12.1% | +14.0% | – | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2017 | FY2021 | FY2026 | Trend |
|---|---|---|---|---|
| Return on equity | 12.8% | 36.8% | 14.9% | |
| Return on assets | 3.3% | 18.7% | 7.6% | |
| Current ratio | 1.52 | 1.91 | 1.89 | |
| Debt to equity | 0.51 | – | – | |
| Net debt to EBITDA | -0.66× | – | – | |
| Interest coverage | 7.8× | 1036.2× | – | |
| Inventory turnover | 1.6× | 2.5× | 2.2× | |
| Capex to revenue | 0.5% | 1.7% | 2.0% | |
| Diluted shares | 14M | 14M | 13M |
Where the cash went
Fiscal 2022 to 2026, five years combined
Lifevantage generated $49.10M from operations and spent $46.37M on capital expenditure, dividends and share buybacks. 25% of that went back into the business.
Generated
$49.10M
Used
$46.37M
Capital expenditure$11.78M25%Dividends$13.32M29%Share buybacks$21.28M46%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin2.8%
×Asset turnover2.72×
×Equity multiplier1.96×
=Return on equity, FY202614.9%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2026 | 2.8% | 2.72× | 1.96× | 14.9% |
| FY2025 | 4.3% | 3.46× | 2.18× | 32.3% |
| FY2024 | 1.5% | 3.17× | 2.08× | 9.7% |
| FY2023 | 1.2% | 3.12× | 2.07× | 7.7% |
| FY2022 | 1.5% | 2.76× | 2.19× | 9.1% |
| FY2021 | 5.9% | 3.20× | 1.96× | 36.8% |
| FY2020 | 5.0% | 4.08× | 1.89× | 38.2% |
| FY2019 | 3.3% | 4.25× | 2.17× | 30.2% |
| FY2018 | 2.8% | 4.22× | 2.64× | 31.6% |
| FY2017 | 0.8% | 4.15× | 3.82× | 12.8% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2026 against fiscal 2025
5of 8 tests passed in fiscal 2026. Some tests lack the figures they need.
- ProfitableNet income above zero$5.07M
- Cash generatingOperating cash flow above zero$10.24M
- Return on assets improvedROA up on the prior year16.3% → 7.0%
- Earnings backed by cashOperating cash flow above net income$10.24M vs $5.07M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose1.87 → 1.89
- No dilutionShare count did not rise13M → 13M
- Gross margin improvedGross margin up on the prior year80.37% → 77.56%
- More efficientAsset turnover rose3.79 → 2.54